NCCN 13th Annual Congress: Hematologic Malignancies™

Agenda

This agenda is subject to change. Faculty will be updated as confirmed.

  • Friday, September 21, 2018
  •  
    4:30 PM  -  6:00 PM
    Registration; Refreshments and Exhibits
    6:00 PM  -  6:10 PM
    Opening Remarks
    6:10 PM  -  7:55 PM
    Keynote Session: CAR T-Cell Therapy
    • Overview/introduction that covers the mechanism of action, historical perspective, major trials, and pipeline (including myeloma)

    • Focus on lymphomas; including management of toxicities

    • Focus on leukemia; including management of toxicities

    7:55 PM  -  8:25 PM
    Consideration for Use of Novel Agents in Acute Myeloid Leukemia
  • Saturday, September 22, 2018
  •  
    7:00 AM  -  8:00 AM
    Registration; Breakfast and Exhibits
    8:00 AM  -  8:05 AM
    Opening Remarks
    8:05 AM  -  9:05 AM
    Patient Case Studies and Panel Discussion: Leukemia and MPN
    • Case 1: Management of AML in the Elderly

    • Case 2: Cardiovascular Toxicities of TKI Therapy in CML

    • Case 3: Management of Systemic Mastocytosis

    9:05 AM  -  9:35 AM
    Sequencing of Second-line and Subsequent TKI Therapy for CP-CML & Discontinuation of TKI Therapy
    9:35 AM  -  10:05 AM
    Prognostic Significance of Mutations (MF, PV and ET)
    10:05 AM  -  10:30 AM
    Break and Exhibits
    10:30 AM  -  11:15 AM
    Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
    • Case 1: Importance of MRD monitoring

    • Case 2: Management of Infections in Multiple Myeloma

    11:15 AM  -  11:45 PM
    Current Approaches to Initial Treatment of Newly Diagnosed Multiple Myeloma
    11:45 AM  -  12:15 PM
    Emerging Options and Sequencing Therapies for Relapsed Multiple Myeloma
    12:15 PM  -  1:30 PM
    Lunch and Exhibits
    1:30 PM  -  2:00 PM
    Management of Bone Health and Bone-related Complications in Patients with Hematologic Malignancies
    2:00 PM  -  3:00 PM
    Patient Case Studies and Panel Discussion: Lymphoma
    • Case 1: Relapsed/Refractory Hairy Cell Leukemia

    • Case 2: Relapsed/Refractory Follicular Lymphoma

    • Case 3: Relapsed/Refractory Nodular Lymphocyte Predominant Hodgkin Lymphoma

    3:00 PM  -  3:30 PM
    CLL: Histologic Transformation and Progression & Management of Relapsed/Refractory Disease
    3:30 PM  -  3:55 PM
    Break and Exhibits
    3:55 PM  -  4:25 PM
    Updates to the Front-line Therapy in Hodgkin Lymphoma
    4:25 PM  -  4:55 PM
    Emerging Options for the Management of Relapsed/Refractory Hodgkin Lymphoma
    4:55 PM  -  5:00 PM
    Closing Remarks
Top